20 August 2004 Laser immunotherapy: a novel approach for metastatic tumors
Author Affiliations +
Abstract
The ideal treatment modality for tumors, particularly for those that metastasize to multiple remote sites, should eradicate the primary tumor and elicit a systemic, tumor-specific response leading to elimination of metastases and to long-term tumor immunity. Using the selective photothermal interaction as a precursor, laser immunotherapy was developed by introducing a novel immunoadjuvant administered in conjunction with the laser-absorbing dye. Specifically, an 805-nm laser and indocyanine green (ICG) was used for the selective photothermal interaction, and a novel immunoadjuvant, glycated chitosan (GC), was used as the immunological stimulant. The laser-ICG-GC combinations has been resulted in the following results in animal studies. (1) Selective destruction of deep target tumor target has been achieved; (2) Eradication of treated primary tumors and regression and disappearance of untreated distant metastases have been observed; (3) Long-term survival of tumor-bearing rats have been resulted; (4) Long-term immunity for resistance to repeated, dose-escalated subsequent tumor challenges has been induced; (5) Tumor-specific immunological responses, after laser immunotherapy treatment, have been detected at cellular and molecular levels. The procedure of laser immunotherapy and major results in animal studies will be summarized and some new results using the immunological enhancement for photodynamic therapy treatment will be presented.
© (2004) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Wei R. Chen, Mladen Korbelik, Kenneth Eugene Bartels, Hong Liu, Robert E. Nordquist, "Laser immunotherapy: a novel approach for metastatic tumors", Proc. SPIE 5474, Saratov Fall Meeting 2003: Optical Technologies in Biophysics and Medicine V, (20 August 2004); doi: 10.1117/12.578319; https://doi.org/10.1117/12.578319
PROCEEDINGS
8 PAGES


SHARE
Back to Top